JP2023517727A5 - - Google Patents

Info

Publication number
JP2023517727A5
JP2023517727A5 JP2022555816A JP2022555816A JP2023517727A5 JP 2023517727 A5 JP2023517727 A5 JP 2023517727A5 JP 2022555816 A JP2022555816 A JP 2022555816A JP 2022555816 A JP2022555816 A JP 2022555816A JP 2023517727 A5 JP2023517727 A5 JP 2023517727A5
Authority
JP
Japan
Prior art keywords
modified bont
asn
administered
cosmetic
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517727A (ja
Filing date
Publication date
Priority claimed from GBGB2003813.9A external-priority patent/GB202003813D0/en
Application filed filed Critical
Publication of JP2023517727A publication Critical patent/JP2023517727A/ja
Publication of JP2023517727A5 publication Critical patent/JP2023517727A5/ja
Priority to JP2026036776A priority Critical patent/JP2026097980A/ja
Pending legal-status Critical Current

Links

JP2022555816A 2020-03-16 2021-03-16 上顔面の皺の処置 Pending JP2023517727A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026036776A JP2026097980A (ja) 2020-03-16 2026-03-09 上顔面の皺の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2003813.9 2020-03-16
GBGB2003813.9A GB202003813D0 (en) 2020-03-16 2020-03-16 Treatment of upper facial lines
PCT/GB2021/050659 WO2021186167A1 (en) 2020-03-16 2021-03-16 Treatment of upper facial lines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026036776A Division JP2026097980A (ja) 2020-03-16 2026-03-09 上顔面の皺の処置

Publications (2)

Publication Number Publication Date
JP2023517727A JP2023517727A (ja) 2023-04-26
JP2023517727A5 true JP2023517727A5 (enExample) 2024-03-19

Family

ID=70453766

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022555816A Pending JP2023517727A (ja) 2020-03-16 2021-03-16 上顔面の皺の処置
JP2026036776A Pending JP2026097980A (ja) 2020-03-16 2026-03-09 上顔面の皺の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026036776A Pending JP2026097980A (ja) 2020-03-16 2026-03-09 上顔面の皺の処置

Country Status (11)

Country Link
US (2) US20230346674A1 (enExample)
EP (1) EP4120997A1 (enExample)
JP (2) JP2023517727A (enExample)
KR (1) KR20220154739A (enExample)
CN (1) CN115279337A (enExample)
AU (1) AU2021238928A1 (enExample)
BR (1) BR112022018457A2 (enExample)
CA (1) CA3166944A1 (enExample)
GB (1) GB202003813D0 (enExample)
TW (1) TW202140522A (enExample)
WO (1) WO2021186167A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
US12011284B2 (en) * 2020-05-19 2024-06-18 Peachy Corp. Systems and methods for preventing and treating wrinkles
GB202206362D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202206361D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206348D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
WO2025093845A1 (en) * 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
AU2023471835A1 (en) * 2023-11-01 2026-04-30 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
DK2154151T3 (da) 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
EP2524963B1 (en) 2011-05-19 2018-10-31 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
MX359480B (es) 2012-05-30 2018-09-28 President And Fellows Of Harvard College Star Neurotoxina botulínica diseñada.
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
RU2746736C2 (ru) 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins

Similar Documents

Publication Publication Date Title
Huang et al. Browlift with botulinum toxin
BR112022018457A2 (pt) Tratamento de linhas faciais superiores
JP3066079B2 (ja) 頭痛を低減する方法
Lowe et al. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet
US20020086036A1 (en) Methods for treating hyperhidrosis
US20020107199A1 (en) Methods of administering botulinum toxin
NZ575334A (en) Cosmetic composition for the treatment of skin and methods thereof
CN107661240B (zh) 一种亚微乳修复原液组合物、其制备方法及包含其的化妆品组合物
SA99200566B1 (ar) مسحضرات توكسين البوتولينيوم botulinum toxia سائلة ثابتة
CN101917960A (zh) 肉毒杆菌毒素复合物的神经毒成分在减少或预防副作用中的应用
US20100068232A1 (en) Methods for treating skin lines and wrinkles and improving skin quality
EP1833571B1 (en) Cosmetic composition for skin application suitable for relaxing expression wrinkles
CN110430892A (zh) 肉毒神经毒素在治疗流涎中的改进的用途
KR20240056478A (ko) 콜라겐 조성물 및 이의 사용 방법
JP2026077675A (ja) 高用量低体積のボツリヌス毒素による顔のシワの治療
US20180066020A1 (en) A cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide
Glaser The use of botulinum toxins to treat hyperhidrosis and gustatory sweating syndrome
JP2025514278A5 (enExample)
de Almeida et al. Glabellar wrinkles: a pilot study of contraction patterns
BR0317132A (pt) Métodos de diagnóstico e tratamento de doença pulmonar intersticial
Birch et al. Botulinum toxoid in the management of gustatory sweating (Frey’s syndrome) after superficial parotidectomy
TW202435908A (zh) 組成物及應用其之注射裝置
Matthews-Brzozowska et al. Mesotherapy–a method of facial skin rejuvenation from an interdisciplinary perspective on improving facial aesthetics
NL2039982A (en) Cosmetic composition
RU2826569C2 (ru) Новые способы применения ботулинического нейротоксина для лечения тремора